AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 10877171 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD p24 antigen with p24 antibody
Number of subjects: 240
Study 10877171 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 RNA with CD4+ lymphocyte percent
Number of subjects: 240
Study 9096815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride conventional gel
Number of subjects: 60
Study 9096815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride thixotropic gel
Number of subjects: 60
Study 9096815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride foam
Number of subjects: 60
Study 9096815 — intervention group
Group type: COMPARATOR
Intervention: 2 percent neutral sodium fluoride solution
Number of subjects: 60
Study 8414860 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 30% lidocaine cream
Number of subjects: 30
Study 8414860 — intervention group
Group type: COMPARATOR
Intervention: Cream base alone (placebo)
Number of subjects: 30
Study 3469166 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline daily for ten days
Number of subjects: 42
Study 3469166 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ofloxacin twice a day for nine days
Number of subjects: 42
Study 31625966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline-coated silver dressings
Number of subjects: 194
Study 31625966 — intervention group
Group type: COMPARATOR
Intervention: Standard sterile dressing (Control)
Number of subjects: 194
Study 31625966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nanocrystalline-coated silver dressings and Standard sterile dressing)
Number of subjects: 194
Study 29072027 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching-based rehabilitation for 8 weeks
Number of subjects: 16
Study 29072027 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with analgesics and physical therapy
Number of subjects: 16
Study 27428534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle destabilization devices during a 4-week rehabilitation program
Number of subjects: 26
Study 27428534 — intervention group
Group type: COMPARATOR
Intervention: No device during a 4-week rehabilitation program
Number of subjects: 26
Study 24587113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with anodal tDCS (N = 10)
Number of subjects: 32
Study 24587113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with cathodal tDCS (N = 11)
Number of subjects: 32
Study 24587113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with sham tDCS (N = 11)
Number of subjects: 32
Study 24587113 — intervention group
Group type: COMPARATOR
Intervention: tDCS (anodal, cathodal, or sham)
Number of subjects: 32
Study 23020674 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1 ng.ml(‐1)
Number of subjects: 50
Study 23020674 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 3 ng.ml(‐1)
Number of subjects: 50
Study 23020674 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 5 ng.ml(‐1)
Number of subjects: 50
Study 23020674 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 50
Study 23020674 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50
Study 23020674 — intervention group
Group type: COMPARATOR
Intervention: Peak amplitude
Number of subjects: 50
Study 20421448 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1996
Study 20421448 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1996
Study 20421448 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 55 years
Number of subjects: 1996
Study 20421448 — intervention group
Group type: COMPARATOR
Intervention: Control (White women)
Number of subjects: 1996
Study 20421448 — intervention group
Group type: COMPARATOR
Intervention: Control (Black women)
Number of subjects: 1996
Study 17630038 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg per day) with atorvastatin
Number of subjects: 752
Study 17630038 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone (placebo group)
Number of subjects: 752
Study 15586874 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 28
Study 15586874 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 28
Study 10779230 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymph node dissection
Number of subjects: 0
Study 10779230 — intervention group
Group type: COMPARATOR
Intervention: Limited lymph node dissection
Number of subjects: 0
Study 9348568 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin plus fluorouracil (5‐FU) 425 mg/m2, days 1 through 5, 28‐day cycle
Number of subjects: 0
Study 9348568 — intervention group
Group type: COMPARATOR
Intervention: Oral leucovorin plus oral UFT (tegafur and uracil) 300 mg/m2, days 1 through 28, 35‐day cycle
Number of subjects: 0
Study 8406150 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 64
Study 8406150 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus pure alcohol
Number of subjects: 64
Study 2939868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1-16 mg day-1 (mean daily dose 11.8 mg)
Number of subjects: 0
Study 2939868 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg day-1 (mean daily dose 94.2 mg)
Number of subjects: 0
Study 30483724 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually assisted body-weight supported locomotor training for 60 days
Number of subjects: 20
Study 30483724 — intervention group
Group type: COMPARATOR
Intervention: Usual care (which might include over-ground walking)
Number of subjects: 20
Study 30483724 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually assisted body-weight supported locomotor training
Number of subjects: 20
Study 28410406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 μg/day for 28 days)
Number of subjects: 28
Study 28410406 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 28
Study 26284719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg) once daily for 6 months
Number of subjects: 900
Study 26284719 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (after 5 to 10 days of tinzaparin) adjusted to maintain INR 2.0-3.0 for 6 months
Number of subjects: 900
Study 23983064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily pregabalin (300 mg daily)
Number of subjects: 177
Study 23983064 — intervention group
Group type: EXPERIMENTAL
Intervention: Once nightly pregabalin (300 mg daily)
Number of subjects: 177
Study 23983064 — intervention group
Group type: COMPARATOR
Intervention: Twice daily pregabalin
Number of subjects: 177
Study 23983064 — intervention group
Group type: COMPARATOR
Intervention: Once nightly pregabalin
Number of subjects: 177
Study 22798004 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 17
Study 22798004 — intervention group
Group type: COMPARATOR
Intervention: Drinking water
Number of subjects: 17
Study 19342179 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 191
Study 19342179 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 191
Study 17540667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 922
Study 17540667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 922
Study 17540667 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 922
Study 17540667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg and 125 mg
Number of subjects: 922
Study 15164813 — intervention group
Group type: COMPARATOR
Intervention: Controlled seizures (C)
Number of subjects: 300
Study 15164813 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled seizures (U)
Number of subjects: 300
Study 10724076 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly resistance training and twice-weekly endurance training for 4 to 8 weeks
Number of subjects: 58
Study 10724076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study 9201083 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (360 ml) during meals
Number of subjects: 14
Study 1447392 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel applied subgingivally (2 applications on days 0 and 7)
Number of subjects: 206
Study 1447392 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling (2 sessions, 1 quadrant on day 0 and 1 quadrant on day 7)
Number of subjects: 206
Study 4042549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (cognitive task)
Number of subjects: 25
Study 4042549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (electronic game)
Number of subjects: 25
Study 4042549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (cognitive task and electronic game)
Number of subjects: 25
Study 4042549 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor stimulation (isoprenaline)
Number of subjects: 25
Study 4042549 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenaline responses
Number of subjects: 25
Study 31371287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid supplementation and in-bed cycle ergometry exercise
Number of subjects: 142
Study 31371287 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study 28741238 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical sleeve gastrectomy with oversewing of the staple line
Number of subjects: 200
Study 28741238 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy without reinforcement of the staple line
Number of subjects: 200
Study 27287731 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 2038
Study 27287731 — intervention group
Group type: EXPERIMENTAL
Intervention: Movie
Number of subjects: 2038
Study 27287731 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2038
Study 27287731 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only control
Number of subjects: 2038
Study 24595047 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (ART commenced at mean age of 8 weeks)
Number of subjects: 44
Study 24595047 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (ART commenced at mean age of 18.5 weeks)
Number of subjects: 44
Study 24595047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WMSA present)
Number of subjects: 44
Study 23921822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine hydrochloride 10 mg
Number of subjects: 25
Study 23921822 — intervention group
Group type: COMPARATOR
Intervention: Ringer acetate (placebo)
Number of subjects: 25
Study 20633156 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 59
Study 20633156 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 59
Study 20633156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume predilution hemodiafiltration (HDF)
Number of subjects: 59
Study 20633156 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from HD to HDF
Number of subjects: 59
Study 20633156 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 59
Study 19099722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early minimal feeding group (n = 48)
Number of subjects: 125
Study 19099722 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-early minimal feeding group (n = 47)
Number of subjects: 125
Study 19099722 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (n = 30)
Number of subjects: 125
Study 19099722 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 125
Study 16368305 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d) for 3 months
Number of subjects: 30
Study 16368305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14645308 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1062
Study 10952120 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of adjuvant paclitaxel/carboplatin
Number of subjects: 331
Study 10952120 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of adjuvant paclitaxel/carboplatin
Number of subjects: 331
Study 8973228 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant)
Number of subjects: 1036
Study 8973228 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (150 mg daily)
Number of subjects: 1036
Study 1330848 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose immunoglobulins (h.d. Ig)
Number of subjects: 49
Study 1330848 — intervention group
Group type: COMPARATOR
Intervention: anti-D immunoglobulins
Number of subjects: 49
Study 31506094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product containing moxidectin (24-48 µg/kg), sarolaner (2-4 mg/kg), and pyrantel (5-10 mg/kg)
Number of subjects: 410
Study 31506094 — intervention group
Group type: COMPARATOR
Intervention: Heartgard® Plus (ivermectin/pyrantel)
Number of subjects: 410
Study 31506094 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin alone (24 µg/kg)
Number of subjects: 410
Study 31506094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner alone (2 mg/kg)
Number of subjects: 410
Study 31506094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 31506094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product (moxidectin, sarolaner, pyrantel)
Number of subjects: 410
Study 27799159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 527
Study 27799159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 527
Study 27799159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 25488946 — intervention group
Group type: EXPERIMENTAL
Intervention: LBN 0.024%
Number of subjects: 413
Study 25488946 — intervention group
Group type: COMPARATOR
Intervention: latanoprost 0.005%
Number of subjects: 413
Study 23824945 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for oncology nurses to discuss CAM use
Number of subjects: 699
Study 23824945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 699
Study 22832861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports participation program
Number of subjects: 23
Study 22832861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 19483077 — intervention group
Group type: COMPARATOR
Intervention: BioCryl (interference screws)
Number of subjects: 54
Study 19483077 — intervention group
Group type: EXPERIMENTAL
Intervention: RigidFix (bioresorbable pins)
Number of subjects: 54
Study 19483077 — intervention group
Group type: COMPARATOR
Intervention: BioCryl and RigidFix
Number of subjects: 54
Study 18041415 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar (10% LCD) cream
Number of subjects: 0
Study 18041415 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate cream (0.1%)
Number of subjects: 0
Study 15604515 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA5 polymorphisms 27376 and 28837 (‐3A/G)
Number of subjects: 3878
Study 15604515 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA5 polymorphisms 27709 (‐1131T/C) and 29085
Number of subjects: 3878
Study 15604515 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA5 polymorphism 29009 (S19W)
Number of subjects: 3878
Study 15604515 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA5 polymorphism 30966
Number of subjects: 3878
Study 15604515 — intervention group
Group type: COMPARATOR
Intervention: No APOA5 polymorphisms
Number of subjects: 3878
Study 11850305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐directed, multidisciplinary intervention (including education of patient and family, social support, review of medication, dietary modification and weight monitoring)
Number of subjects: 0
Study 10817086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg
Number of subjects: 265
Study 10817086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 265
Study 10817086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 7562170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implant‐retained overdentures
Number of subjects: 90
Study 7562170 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dentures with preprosthetic surgery
Number of subjects: 90
Study 7562170 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures without preprosthetic surgery (control group)
Number of subjects: 90
Study 7562170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures retained by dental implants
Number of subjects: 90
Study 2338386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% ophthalmic suspension
Number of subjects: 34
Study 2338386 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study 373988 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (480 mg trimethoprim and 2400 mg sulphamethoxazole) per day
Number of subjects: 126
Study 373988 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 2 g per day
Number of subjects: 126
Study 29113874 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg, p.o.)
Number of subjects: 30
Study 29113874 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (5 mg, p.o.)
Number of subjects: 30
Study 29113874 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 28821336 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% hematocrit trigger (low group)
Number of subjects: 722
Study 28821336 — intervention group
Group type: COMPARATOR
Intervention: 28% hematocrit trigger (high group)
Number of subjects: 722
Study 25751701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (12 weeks of analgesic treatment and optimization, followed by 12 weeks of cognitive behavioral therapy)
Number of subjects: 241
Study 25751701 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 23808902 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year adjuvant imatinib therapy
Number of subjects: 0
Study 23808902 — intervention group
Group type: COMPARATOR
Intervention: 1-year adjuvant imatinib therapy
Number of subjects: 0
Study 20647943 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days per week (4D) training volume, n = 60
Number of subjects: 240
Study 20647943 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days per week (3D) training volume, n = 60
Number of subjects: 240
Study 20647943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days per week (2D) training volume, n = 60
Number of subjects: 240
Study 20647943 — intervention group
Group type: COMPARATOR
Intervention: Control group (C), n = 60, no training
Number of subjects: 240
Study 19230614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day intensive self-experience workshop emphasizing healthy lifestyle and behavior-modifying techniques (n=209)
Number of subjects: 323
Study 19230614 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=114)
Number of subjects: 323
Study 19230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 323
Study 17348225 — intervention group
Group type: EXPERIMENTAL
Intervention: Targis inlays
Number of subjects: 345
Study 17348225 — intervention group
Group type: COMPARATOR
Intervention: Composite resin inlays
Number of subjects: 345
Study 15446778 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 2000
Study 15446778 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU twice daily)
Number of subjects: 2000
Study 15446778 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 2000
Study 11398514 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione in erythrocyte lysate
Number of subjects: 30
Study 11398514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma superoxide dismutase activity
Number of subjects: 30
Study 11398514 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glutathione peroxidase
Number of subjects: 30
Study 9024009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 micrograms/kg)
Number of subjects: 40
Study 9024009 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 40
Study 8490166 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (3.45 to 11.50 micrograms/kg/d, subcutaneously)
Number of subjects: 123
Study 3318375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (329 mg daily)
Number of subjects: 0
Study 3318375 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (80 mg daily)
Number of subjects: 0
Study 3318375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem
Number of subjects: 0
Study 3318375 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 28945617 — intervention group
Group type: EXPERIMENTAL
Intervention: In-classroom training with live feedback from NBI expert
Number of subjects: 20
Study 28945617 — intervention group
Group type: COMPARATOR
Intervention: Self-directed training with automated audio feedback
Number of subjects: 20
Study 27744447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 102
Study 27744447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CT + Paroxetine)
Number of subjects: 102
Study 27744447 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 102